论文部分内容阅读
目的观察莫沙必利片联合盐酸特拉唑嗪片治疗糖尿病神经源性膀胱的临床疗效。方法 42例糖尿病神经源性膀胱患者,随机分为治疗组和对照组,每组21例。治疗组采用莫沙比利+盐酸特拉唑嗪片治疗,对照组采用维生素B1针及甲钴胺针治疗,治疗2周后,比较治疗前后两组患者B超测定膀胱残余尿量的变化及患者主观症状。结果治疗组治愈率为95.2%高于对照组的61.9%(P<0.05)。治疗后两组患者B超残余尿量均较治疗前减少,治疗组减少情况优于对照组(P<0.05);治疗组消化道症状、血压、药物相关副作用不良反应发生率低于对照组,差异有统计学意义(P<0.05);两组肢端感觉异常情况比较差异无统计学意义(P>0.05)。结论莫沙比利与盐酸特拉唑嗪联合应用,治疗糖尿病神经源性膀胱是有效可行的,可在临床广泛应用。
Objective To observe the clinical efficacy of mosapride tablets and terazosin hydrochloride tablets in the treatment of diabetic neurogenic bladder. Methods Forty-two patients with diabetic neurogenic bladder were randomly divided into treatment group (n = 21) and control group (n = 21). The treatment group treated with mosapride + terazosin hydrochloride tablets, the control group with vitamin B1 and mecobalamin needle treatment, after 2 weeks of treatment, the two groups before and after treatment B changes in the determination of bladder residual urine volume and Subjective symptoms of patients. Results The cure rate of the treatment group was 95.2% higher than that of the control group (61.9%, P <0.05). The residual urine volume of B group in treatment group was lower than that in the control group before treatment, and the decrease in the treatment group was better than that in the control group (P <0.05). The adverse reactions of gastrointestinal symptoms, blood pressure and drug-related side effects in the treatment group were lower than those in the control group The difference was statistically significant (P <0.05). There was no significant difference between the two groups (P> 0.05). Conclusion Mosapride combined with terazosin hydrochloride in the treatment of diabetic neurogenic bladder is effective and feasible, and can be widely used in clinical practice.